Reactivated ocular toxoplasmosis
ICD-10 B58.0 · ICD-11 1F57.3/9B65.1

What Is the Treatment of Reactivated Ocular Toxoplasmosis?

Reactivated ocular toxoplasmosis presents as active toxoplasmic retinochoroiditis requiring prompt, structured treatment to achieve lesion resolution and preserve vision.

Treatment Approach

Management involves combination antimicrobial therapy alongside a systemic corticosteroid, sustained over a multi-week course — with the appropriate regimen determined by the specific clinical situation.

The full combination options, sequencing, and adjunctive considerations are outlined in the complete protocol.

Clinical Goal

The objective is resolution of the active retinochoroiditis, typically expected within 1 to 2 months.

Instant Access to Structured Evidence-Based Regimens
References

DOI: 10.1007/s10792-021-01994-9

  • The treatment of ocular toxoplasmosis includes both antimicrobial drugs and corticosteroids (topical and oral) and is maintained for 4–6 weeks.
  • The 'classic therapy' consists of pyrimethamine, sulfadiazine and a systemic corticosteroid (most commonly prednisone).
  • Typically, toxoplasmic retinochoroiditis in immunocompetent patients is expected to resolve within 1 to 2 months.
View source ↗